RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 1 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug tested for Tough-to-Treat blood cancers
Disease control OngoingThis is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo aims to tame resistant blood cancers
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for patients when CAR-T fails: immunotherapy trial targets stubborn blood cancers
Disease control OngoingThis study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug trial targets stubborn blood cancer
Disease control OngoingThis study tested a daily pill called ibrutinib in 41 patients with follicular lymphoma, a type of blood cancer, that had returned or stopped responding to previous treatments. The main goal was to see how well the drug could shrink the cancer and control the disease. Researchers…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo therapy aims to fight back against stubborn blood cancer
Disease control TerminatedThis study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this two-drug approach can help control the cance…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New combo therapy tested for Tough-to-Treat lymphomas
Disease control OngoingThis study is testing whether combining the immunotherapy drug pembrolizumab with the standard antibody rituximab (with or without the drug lenalidomide) can help control lymphoma that has come back after previous treatment. It is for adults with specific types of B-cell lymphoma…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Scientists test powerful new drug cocktail to fight back against tough lymphomas
Disease control OngoingThis early-stage study is testing a new combination of three drugs for people whose non-Hodgkin's lymphoma has come back after prior treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and …
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Engineered immune cells target cancer in groundbreaking lymphoma trial
Disease control OngoingThis early-phase study is testing a new type of cell therapy for patients with high-risk or returning B-cell non-Hodgkin lymphoma. After receiving a stem cell transplant, patients get an infusion of their own immune cells that have been genetically modified in a lab to better fin…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: RECURRENT GRADE 1 FOLLICULAR LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC